enGene Therapeutics Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Oct 2021 | — | $-53.4M | $11.0M |
| Oct 2022 | — | $-76.6M | $20.4M |
| Jan 2023 | — | $-84.0M | — |
| Apr 2023 | — | $-89.2M | — |
| Jul 2023 | — | $-93.9M | — |
| Oct 2023 | — | $72.5M | $81.5M |
| Jan 2024 | — | $62.4M | $85.6M |
| Apr 2024 | — | $243.0M | $264.8M |
| Jul 2024 | — | $230.3M | $257.7M |
| Oct 2024 | — | $272.6M | $173.0M |
| Jan 2025 | — | $250.0M | $62.3M |
| Apr 2025 | — | $227.3M | $57.5M |
| Jul 2025 | — | $200.7M | $32.6M |
| Oct 2025 | — | $167.7M | $50.2M |
| Jan 2026 | — | $281.5M | $36.6M |
| Apr 2026 | — | $255.2M | $29.8M |
| Jul 2026 | — | $230.3M | $41.0M |